Indo US Bio-Tech Ltd

Indo US Bio-Tech Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 19 January 2026. However, the analysis and financial metrics presented here reflect the company’s current position as of 15 April 2026, providing investors with an up-to-date view of its fundamentals, returns, and overall outlook.

Indo US Bio-Tech Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 19 January 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 04 April 2026, providing investors with the latest insights into the company’s performance and outlook.

Indo US Bio-Tech Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 19 January 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 24 March 2026, providing investors with the latest insights into its performance and outlook.

Indo US Bio-Tech Ltd, a micro-cap player in the Other Agricultural Products sector, has touched a fresh 52-week low of Rs.95 today, marking a significant decline in its stock price amid broader market pressures and company-specific performance issues.

Indo US Bio-Tech Ltd’s stock declined to a fresh 52-week low of Rs.96 on 13 Mar 2026, marking a significant drop amid a broader sectoral slump and subdued market conditions. The stock’s performance reflects ongoing pressures within the Other Agricultural Products sector, which has seen a notable downturn over recent months.

Indo US Bio-Tech Ltd’s shares touched a new 52-week low of Rs.96.9 today, marking a significant decline amid a broader market downturn. The stock has been on a downward trajectory for five consecutive sessions, shedding 28.58% in returns during this period, reflecting ongoing pressures within the Other Agricultural Products sector.

Indo US Bio-Tech Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 19 January 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 12 March 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

Indo US Bio-Tech Ltd’s stock declined to a fresh 52-week low of Rs.97.65 today, marking a significant milestone in its ongoing downward trajectory. The stock has underperformed both its sector and broader market indices, reflecting a combination of recent quarterly results and longer-term performance trends.

Indo US Bio-Tech Ltd, a key player in the Other Agricultural Products sector, has seen a significant shift in its valuation parameters, moving from an attractive to a very attractive rating. Despite a sharp decline in its share price and a downgrade in its overall mojo grade to Sell, the company’s price-to-earnings (P/E) and price-to-book value (P/BV) ratios now present a compelling case for value investors seeking opportunities in a volatile market.

Indo US Bio-Tech Ltd, a player in the Other Agricultural Products sector, has declined to a fresh 52-week low of Rs.104.85 on 9 Mar 2026, marking a significant downturn amid broader market volatility and sectoral weakness.

Indo US Bio-Tech Ltd is rated Sell by MarketsMOJO, with this rating last updated on 19 January 2026. However, the analysis and financial metrics presented here reflect the stock’s current position as of 26 February 2026, providing investors with the most recent and relevant data to assess the company’s outlook.

Indo US Bio-Tech Ltd, a key player in the Other Agricultural Products sector, has recently experienced a notable shift in its valuation parameters, moving from an attractive to a fair rating. This change reflects evolving market perceptions amid fluctuating price-to-earnings (P/E) and price-to-book value (P/BV) ratios, alongside comparisons with industry peers and historical benchmarks. Investors are now reassessing the stock’s price attractiveness in light of these developments.

Indo US Bio-Tech Ltd is rated Sell by MarketsMOJO, with this rating last updated on 19 January 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 13 February 2026, providing investors with the most recent and relevant data to assess the company’s outlook.

Indo US Bio-Tech Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 19 January 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 02 February 2026, providing investors with the latest insights into the company’s performance and outlook.

Indo US Bio-Tech Ltd has reported a significant downturn in its latest quarterly financial performance, marking a shift from a previously flat to a negative financial trend. The company’s December 2025 quarter results reveal contraction across key metrics including revenue, profitability, and earnings per share, signalling challenges ahead for this player in the Other Agricultural Products sector.

Indo US Bio-Tech Ltd’s stock declined sharply to a new 52-week low of Rs.109.7 today, marking a significant drop amid a challenging market environment and subdued financial performance. The stock’s fall contrasts with the broader market’s mixed movements, highlighting company-specific pressures.

Indo US Bio-Tech Ltd, a player in the Other Agricultural Products sector, has seen its investment rating downgraded from Hold to Sell as of 19 Jan 2026. This shift reflects deteriorating technical indicators, flat recent financial performance, and a challenging near-term outlook despite some strong long-term fundamentals. The company’s Mojo Score has declined to 47.0, signalling caution for investors amid a 3.8% drop in share price on the downgrade day.